Ethan A. Natelson, M.D.
Internal Medicine Residency, Baylor College of Medicine, Houston, TX
After completing his postdoctoral training at the Baylor College of Medicine in Houston,Texas, Dr. Natelson became an Instructor there in the Department of Medicine in 1972. He was promoted to Assistant Professor the following year, and Clinical Assistant Professor of Medicine in 1975. He also received a faculty appointment as a Clinical Associate Professor of Medicine from The University of Texas Health Science Center at Houston in 1975, an appointment he still holds today. Dr. Natelson first joined the active staff at The Methodist Hospital in 1972 and became the Director of the Translational Internship Program there in 2006. He became the Chair of the second Institutional Review Board at The Methodist Hospital Research Institute when it was established in 2009.
Dr. Natelson’s research focuses on the development and evaluation of novel cancer therapeutics, as well as investigations into possible environmental causes of various cancers.
Pancreatic cancer, myelodysplasia, sideroblastic erythropoiesis, myeloid leukemia, lymphohematopoietic malignancy.
Natelson EA, Pyatt D. Temozolomide-induced myelodysplasia. Adv Hematol. 2009. In Press.
Pyatt D, Natelson E, Golden R. Is inhalation exposure to formaldehyde a biologically plausible cause of lymphohematopoietic malignancies? Regul Toxicol Pharmacol. 2008 Jun;51(1):119-33.
Natelson EA. Benzene exposure and refractory sideroblastic erythropoiesis: is there an association? Am J Med Sci. 2007 Nov;334(5):356-60.
Natelson EA. Benzene-induced acute myeloid leukemia: a clinician's perspective. Am J Hematol. 2007 Sep;82(9):826-30.
Natelson EA. Pregnancy-induced pancytopenia with cellular bone marrow: distinctive hematologic features. Am J Med Sci. 2006 Oct;332(4):205-7.
Natelson EA. Myelodysplasia with isolated trisomy 15: a 15-year follow-up without specific therapy. Am J Med Sci. 2006 Mar;331(3):157-8.